Drug makers Sanofi and UCB have poured in another $27 million into New York-based healthcare analytics provider Aetion. Previous investors included Amgen Ventures, McKesson Ventures, Horizon Health Services, NEA, Flare Capital, and Lakestar.
More information about Aetion can be found in this post from MedCityNews:
The investment caps a $63 million Series B funding round and brings the total amount of funding the company has received to $77 million since it was launched in 2015.
Aetion plans to use the funding to build up its product, the Aetion Evidence Platform, and move into therapeutic area-related intelligence, outcomes-based contracting for payers and promote RWE globally. It noted that RWE is particularly important for value-based care.
The company’s focus is on real-world evidence, delivered through the platform, which analyzes data to produce what it calls transparent, rapid and scientifically validated answers on treatments, costs and outcomes. “We’re entering a new era in which nearly the entire healthcare ecosystem – from biopharma and regulators to payers and technology companies – recognizes the importance of using real-world evidence to reduce the time and cost to bring new therapies to market,” CEO Carolyn Magill said in a statement. “This funding demonstrates that the industry’s leaders, who are using our technology to drive healthcare’s most critical decisions, view Aetion as a trusted partner vital to their long-term success.”
